| scholarly article | Q13442814 |
| P356 | DOI | 10.1681/ASN.2006090987 |
| P698 | PubMed publication ID | 17229917 |
| P2093 | author name string | Catheline Vilain | |
| Gilbert Vassart | |||
| Guy Decaux | |||
| Frédéric Vandergheynst | |||
| Jasmine Parma | |||
| Yasmina Bouko | |||
| P433 | issue | 2 | |
| P921 | main subject | nephrogenic syndrome of inappropriate antidiuresis | Q55782451 |
| P304 | page(s) | 606-612 | |
| P577 | publication date | 2007-01-17 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree | |
| P478 | volume | 18 |
| Q34260031 | A copeptin-based classification of the osmoregulatory defects in the syndrome of inappropriate antidiuresis |
| Q33675310 | Absence of AVPR2 copy number variation in eunatremic and dysnatremic subjects in non-Hispanic Caucasian populations |
| Q50192139 | Adult female with symptomatic AVPR2-related nephrogenic syndrome of inappropriate antidiuresis (NSIAD). |
| Q37155408 | Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis. |
| Q30277654 | American Society of Nephrology Quiz and Questionnaire 2015: Electrolytes and Acid-Base Disorders |
| Q36328081 | Clinical management of SIADH. |
| Q90028584 | Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis |
| Q35673634 | Cyclophosphamide-induced vasopressin-independent activation of aquaporin-2 in the rat kidney |
| Q36017723 | Determining factors of diuresis in chronic kidney disease patients initiating hemodialysis. |
| Q26747663 | Efficacy and Safety of Vasopressin Receptor Antagonists for Euvolemic or Hypervolemic Hyponatremia: A Meta-Analysis |
| Q38449311 | Employment of vasopressin receptor antagonists in management of hyponatraemia and volume overload in some clinical conditions. |
| Q30249421 | Epidemiology, pathophysiology and putative genetic basis of carbamazepine- and oxcarbazepine-induced hyponatremia |
| Q52652712 | Focus on neonatal and infantile onset of nephrogenic syndrome of inappropriate antidiuresis: 12 years later. |
| Q33862041 | Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments |
| Q36737665 | Functional polymorphisms affecting the clinically important arginine-137 residue of AVPR2 do not influence serum sodium concentration at the population level |
| Q37837505 | G protein-coupled receptors: mutations and endocrine diseases |
| Q35786320 | Heritability of serum sodium concentration: evidence for sex- and ethnic-specific effects |
| Q43734962 | How I approach hyponatraemia. |
| Q37799214 | Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) |
| Q35626444 | Hyponatremia secondary to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): therapeutic decision-making in real-life cases |
| Q34619597 | Hyponatremia: evaluation and management |
| Q36280354 | Identification and characterization of an activating F229V substitution in the V2 vasopressin receptor in an infant with NSIAD. |
| Q37706095 | Impaired Urine Dilution Capability in HIV Stable Patients. |
| Q43460589 | Lack of responsiveness to 1-desamino-D arginin vasopressin (desmopressin) in male patients with nephrogenic syndrome of inappropriate antidiuresis: from bench to bedside |
| Q66684724 | Language of the other |
| Q33635249 | Long-term outcomes in a family with nephrogenic syndrome of inappropriate antidiuresis |
| Q37832491 | Management of hypotonic hyponatremia |
| Q42479144 | Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis. |
| Q37137434 | Mutations of Vasopressin Receptor 2 Including Novel L312S Have Differential Effects on Trafficking. |
| Q46486658 | Neonatal onset of nephrogenic syndrome of inappropriate antidiuresis. |
| Q90540541 | Nephrogenic Diabetes Insipidus |
| Q36724058 | Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. |
| Q35821143 | Nephrogenic syndrome of inappropriate antidiuresis |
| Q38682478 | Nephrogenic syndrome of inappropriate antidiuresis secondary to an activating mutation in the arginine vasopressin receptor AVPR2. |
| Q34777664 | Non-peptide arginine-vasopressin antagonists: the vaptans |
| Q54411907 | Novel de novo PCDH19 mutations in three unrelated females with epilepsy female restricted mental retardation syndrome |
| Q37234799 | Novel diuretic targets |
| Q51850072 | Novel intragenic deletion in OPHN1 in a family causing XLMR with cerebellar hypoplasia and distinctive facial appearance. |
| Q35822304 | Persistent elevation of urine aquaporin-2 during water loading in a child with nephrogenic syndrome of inappropriate antidiuresis (NSIAD) caused by a R137L mutation in the V2 vasopressin receptor |
| Q30240732 | Physiopathology, clinical diagnosis, and treatment of hyponatremia |
| Q37488699 | Retrospective evaluation of standard diagnostic procedures in identification of the causes of new-onset syndrome of inappropriate antidiuresis |
| Q57299450 | Salt, water and nephron: Mechanisms of action and link to hypertension and chronic kidney disease |
| Q35275760 | Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia. |
| Q33520239 | The constitutively active V2 receptor mutants conferring NSIAD are weakly sensitive to agonist and antagonist regulation |
| Q38190864 | The long-term complications of the inherited tubulopathies: an adult perspective |
| Q46121480 | The vaptans ante portas: a status report |
| Q38793835 | Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants |
| Q47925751 | Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial |
| Q33550630 | V2R mutations and nephrogenic diabetes insipidus. |
| Q37058365 | Vaptans and hyponatremia in critical patients |
| Q37833895 | Vaptans for the treatment of hyponatremia |
| Q96136398 | Vasopressin receptor 2 mutations in the nephrogenic syndrome of inappropriate antidiuresis show different mechanisms of constitutive activation for G protein coupled receptors |
| Q42786149 | Vasopressin receptor antagonists: the vaptans |
| Q36357468 | Vasopressin regulates renal calcium excretion in humans |
| Q64232310 | Vasopressin-aquaporin-2 pathway: recent advances in understanding water balance disorders |
| Q37770574 | Vasopressin-receptor antagonists |
| Q26770753 | Water, electrolytes, and acid-base alterations in human immunodeficiency virus infected patients |
| Q38068780 | Where vaptans do and do not fit in the treatment of hyponatremia |
| Q91939949 | [Nephrogenic syndrome of inappropriate antidiuresis] |
Search more.